azelaic acid gel / Generic mfg. - LARVOL DELTA

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Wake Forest University Health Sciences | Trial primary completion date: Jun 2026 ➔ Nov 2026

Trial primary completion date • Alopecia • Dermatology • Immunology

Comparative Efficacy of 10% Azelaic Acid Versus 1% Metronidazole in the Treatment of Mild to Moderate Rosacea: A Randomized Controlled Study in Vietnamese Patients (EADV-Sp 2026) - "Materials and Methods In this randomized controlled trial, 60 patients with mild to moderate rosacea were allocated 1:1 to receive either 10% Azelaic Acid gel or 1% Metronidazole gel, applied twice daily, in conjunction with oral Doxycycline 100mg once daily for 12 weeks. Mild local adverse effects were more frequent with azelaic acid, with itching reported in 81.2% versus 57.1% and stinging in 60% versus 55.6% of patients, respectively Conclusions Both 10% azelaic acid and 1% metronidazole, in combination with doxycycline 100 mg, are effective for mild to moderate rosacea. Azelaic acid demonstrates slightly superior clinical efficacy but is associated with a higher incidence of mild, transient local irritation."

Clinical • Dermatitis • Dermatology • Immunology • Pruritus • Rosacea

Insurance Coverage of Rosacea Topicals: A Cross-Sectional Review (AAD 2026) - " Azelaic acid gel, oxymetazoline hydrochloride cream, ivermectin cream, sulfacetamide sodium–sulfur cleanser, metronidazole gel, minocycline foam, brimonidine gel, and Epsolay benzoyl peroxide (BPO) cream were reviewed across UnitedHealth Group, Elevance (Anthem), CVS Health (Aetna), Cigna, Health Care Service Corporation Blue Cross Blue Shield (BCBS), Kaiser Permanente, BCBS Florida, BCBS Michigan, Centene, and Blue Shield of California. Only two rosacea topicals were consistently covered by major commercial insurers, and many plans imposed quantity limits and step therapy barriers. Interestingly, metronidazole, identified as less effective than the uncovered topicals, was the most covered agent. [5] This disconnect between evidence-based rosacea treatments and insurer restrictions underscores the need for reform and improved access."

Reimbursement • Review • US reimbursement • Dermatology • Inflammation • Rosacea

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: Wake Forest University Health Sciences | Recruiting ➔ Active, not recruiting

Enrollment closed • Alopecia • Dermatology • Immunology

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Efficacy and Safety of Azelaic Acid and Azelaic Acid Combined with Compound Acid in the Treatment of Post-Inflammatory Erythema and Pigmentation of Acne: A Single-center, Prospective, Randomized Controlled Clinical Study Protocol (ChiCTR) - P=N/A | N=64 | Not yet recruiting | Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University

New trial • Acne Vulgaris • Dermatology

Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris (EADV 2024) - "The results indicate that 15% AzA gel effectively improved acne-induced PIE and PIH with minimal adverse reactions, making it a viable clinical application. In the study population, it had no adverse effects on skin barrier function and contributed positively to acne improvement and patient quality of life."

Acne Vulgaris • Dermatology

Evaluation of a cosmetic foam containing 15% azelaic acid for mild to moderate acne in Chinese patients (EADV 2024) - "We developed an azelaic acid foam specifically for this population... The efficacy results after 4 weeks suggest a stable and continuous activity of the product in reducing the severity of acne, promoting the regression of the inflammatory papules, and improving barrier function. Figure 1 Table 1 W0 W2 W4 skin hydration (%) 48.98±11.72 52.06±8.64 58.64±8.56* TEWL (g/hm2) 27.07±7.73 23.27±6.28* 23.09±7.06* casual sebum (μ g/cm2) 148.44±51.38 140.44±49.24 118.59±44.81* Table 2 W0 W2 W4 Sensitivity Skin tightness intensity 2.55 2.07 -18.90% ↓ Skin tightness frequency 2.32 1.80 -22.50% ↓ Skin turgor 0.35 0.20 -43.64% ↓ Skin scale 0.45 0.33 -26.19% ↓ Skin redness 0.42 0.33 -20.51% ↓ Overall healthy 1.45 1.63 12.52% ↑ Skin texture Coarse pore 1.94 1.73 -10.44% ↓ Skin oiliness 1.90 1.53 -19.44% ↓ Comedones Comedo number 1.74 1.50 -13.89% ↓ Comedo area 1.45 1.33 -8.15% ↓ Comedo extent 1.58 1.47 -7.21% ↓ Comedo size 1.26 1.20 -4.62% ↓..."

Clinical • Acne Vulgaris • Pruritus

Evaluation of the effects of 5% and 10% azelaic acid foam on sebum and acne lesions in Chinese acne patients (EADV 2024) - "This study demonstrated excellent efficacy of both concentrations of azelaic acid foam in reducing sebum secretion and the number and area of comedone lesions. 10% azelaic acid foam is more suitable for acne patients with oily skin. Figure 1 Figure 2 Table 1 Before testing (D0) D3 D7 D28 5% azelaic acid foam 6.17 5.97 5.43* 4.63* Percentage reduction / 3.24% 11.89% 24.86% 10% azelaic acid foam 6.93 6.57* 5.97* 5.10* Percentage reduction / 5.19% 13.85% 26.41%"

Clinical • Acne Vulgaris

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Wake Forest University Health Sciences | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia • Dermatology • Immunology

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Alopecia • Dermatology • Immunology

Combination treatment on clinical improvement in rosacea patients (EADV-Sp 2024) - "The 1 group of 15 patients received pulsed dye laser (PDL) 595 nm procedures and topical therapy with 15% azelaic acid gel in combination with 1% ivermectin cream... All patients tolerated the treatment satisfactorily; no side effects were registered, which indicates the possibility of combined use of azelaic acid and ivermectin preparations in combination with botulinum therapy with incobotulinumtoxinA and PDL 595nm... According to the data of assessment of the dynamics of the DISS scale, the IGA index, DLQI the effectiveness of therapy of all treatment methods in relation to inflammatory, local and diffuse erythema is shown. Combination therapies are effective against both vascular and inflammatory components, local and diffuse erythema and increase patient satisfaction, represent a promising approach to the treatment of patients with erythematotelangiectatic and papulopustular subtypes of Rosacea."

Clinical • Dermatology • Dermatopathology • Rosacea

Combination treatment on clinical improvement in rosacea patients (EADV-Sp 2024) - "The 1 group of 15 patients received pulsed dye laser (PDL) 595 nm procedures and topical therapy with 15% azelaic acid gel in combination with 1% ivermectin cream... All patients tolerated the treatment satisfactorily; no side effects were registered, which indicates the possibility of combined use of azelaic acid and ivermectin preparations in combination with botulinum therapy with incobotulinumtoxinA and PDL 595nm... According to the data of assessment of the dynamics of the DISS scale, the IGA index, DLQI the effectiveness of therapy of all treatment methods in relation to inflammatory, local and diffuse erythema is shown. Combination therapies are effective against both vascular and inflammatory components, local and diffuse erythema and increase patient satisfaction, represent a promising approach to the treatment of patients with erythematotelangiectatic and papulopustular subtypes of Rosacea."

Clinical • Dermatology • Dermatopathology • Rosacea

Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris. (PubMed, Dermatol Ther (Heidelb)) - "The results indicate that 15% AzA gel effectively improved acne-induced PIE and PIH with minimal adverse reactions, making it a viable clinical application. In the study population, it had no adverse effects on skin barrier function and contributed positively to acne improvement and patient quality of life."

Clinical • Journal • Acne Vulgaris • Dermatology

15% azelaic acid gel efficacy on acne erythema and pigmentation (SID 2024) - No abstract available

Clinical • Acne Vulgaris • Dermatology

Microencapsulated Benzoyl Peroxide for Rosacea in Context: A Review of the Current Treatment Landscape. (PubMed, Drugs) - "It evaluates the efficacy, safety, and tolerability of various US Food and Drug Administration (FDA)-approved agents used for rosacea treatment, including E-BPO cream, metronidazole gel, azelaic acid gel and foam, ivermectin cream, minocycline foam, oral doxycycline, brimonidine gel, and oxymetazoline HCl cream...Further research is necessary to determine the exact role of E-BPO 5% in the therapeutic landscape for rosacea. However, based on available evidence, E-BPO 5% shows potential as a valuable treatment option for managing inflammatory lesions of rosacea, and it may offer benefits to patients including: rapid onset of action, demonstrated efficacy by Week 2, excellent tolerability, and sustained long-term results for up to 52 weeks of treatment."

Journal • Review • Dermatology • Rosacea

Comparison table: Some topical drugs for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Drugs for rosacea. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Dermatology • Rosacea

Efficacy of combination therapy in patients with rosacea (EADV 2023) - "The first group of 12 patients received pulsed dye laser (PDL, with a wavelength of 595 nm) procedures and topical therapy with 15% azelaic acid gel in combination with 1% ivermectin cream...In the second group, 12 patients received intradermal injections of incobotulinumtoxinA in the area of redness with an interval of 1 cm between injections in combination with topical therapy with azelaic acid and ivermectin creams... Laser therapy PDL 595 nm is a leader in the treatment of individual telangiectasias and vascular pattern. Topical application of azelaic acid in combination with ivermectin shows a reduction in the inflammatory component in the form of pustules. Combination therapies are effective against both vascular and inflammatory components and represent a promising approach to the treatment of patients with erythematoteleangiectatic and papulopustular subtypes of Rosacea."

Clinical • Combination therapy • Dermatology • Dermatopathology • Inflammation • Rosacea

The efficacy of combination therapy in patients with rosacea (EADV 2023) - "The first group of 12 patients received pulsed dye laser (PDL, with a wavelength of 595 nm) procedures and topical therapy with 15% azelaic acid gel in combination with 1% ivermectin cream...In the second group, 12 patients received intradermal injections of incobotulinumtoxinA in the area of redness with an interval of 1 cm between injections in combination with topical therapy with azelaic acid and ivermectin creams... Laser therapy PDL 595 nm is a leader in the treatment of individual telangiectasias and vascular pattern. Topical application of azelaic acid in combination with ivermectin shows a reduction in the inflammatory component in the form of pustules. Combination therapies are effective against both vascular and inflammatory components and represent a promising approach to the treatment of patients with erythematoteleangiectatic and papulopustular subtypes of Rosacea."

Clinical • Combination therapy • Dermatology • Dermatopathology • Inflammation • Rosacea

Adult female acne: long-term follow-up after use of azelaic acid in the treatment, and during the maintenance phase (EADV 2023) - "Maintenance therapy brings significant improvement in the reduction of lesions in women with mild and moderate adult acne. As much as possible, systemic therapy is the choice, and anti-androgens, particularly spironolactone, which is considered the first option in association with topical agents, such as 15% azelaic acid gel, used twice a day. This is the best topical regimen."

Clinical • Acne Vulgaris • Dermatitis • Immunology • Seborrheic Dermatitis

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Mar 2024 ➔ Dec 2024 | Trial primary completion date: Nov 2023 ➔ Jun 2024

Trial completion date • Trial primary completion date • Alopecia

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2023 ➔ Mar 2024

Trial completion date • Alopecia

Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Jul 2023 ➔ Dec 2023

Trial completion date • Alopecia